Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium.
Robert Wilhelm KoivulaIan M ForgieAzra KurbasicAna ViñuelaAlison HeggieGiuseppe N GiordanoTue H HansenMichelle HudsonAnitra D M KoopmanFemke RuttersMaritta SiloahoKristine H AllinSøren BrageCaroline A BrorssonAdem Y DawedFederico De MasiChristopher J GrovesTarja KokkolaAnubha MahajanMandy H PerrySimone P RauhMartin RidderstråleHarriet J A TeareE Louise ThomasAndrea TuraHenrik VestergaardTom WhiteJerzy AdamskiJimmy D BellJoline W BeulensSøren BrunakEmmanouil T DermitzakisPhilippe FroguelGary FrostRamneek GuptaTorben HansenAndrew HattersleyBernd JablonkaJane KayeMarkku LaaksoTimothy J McDonaldOluf PedersenJochen M SchwenkImre PavoAndrea MariMark I McCarthyHartmut RuettenMark WalkerEwan R PearsonPaul W Franksnull nullPublished in: Diabetologia (2019)
The IMI DIRECT cohorts are intensely characterised, with a wide-variety of metabolically relevant measures assessed prospectively. We anticipate that the cohorts, made available through managed access, will provide a powerful resource for biomarker discovery, multivariate aetiological analyses and reclassification of patients for the prevention and treatment of type 2 diabetes.